Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD
Abstract
Objective: This study evaluates dexmethylphenidate extended release (d-MPH-ER) in adults with ADHD. Method: Following a 5-week, randomized, controlled, fixed-dose study of d-MPH-ER 20 to 40 mg/d, 170 adults entered a 6-month open-label extension (OLE) to assess long-term safety, with flexible dosing of 20 to 40 mg/d. Exploratory effectiveness outcomes included change from Week 5 on ADHD Rating Scale (ADHD-RS) and proportion of responders on Clinical Global Impressions—Improvement (CGI-I) scale. Results: 103 patients completed OLE, and effectiveness was evaluable in 102 patients. d-MPH-ER was well tolerated; the most common adverse events (>15%) were headache, insomnia, and decreased appetite. Mean improvements in ADHD-RS score were −10.2 for patients switched from placebo to d-MPH-ER ( n = 20) and −8.4 for those maintained on d-MPH-ER ( n = 82). Respective CGI-I responder rates were 95.0% and 95.1%. Conclusion: Once-daily d-MPH-ER 20 to 40 mg is safe and effective for long-term treatment of adult ADHD. (J. of Att. Dis. 2009; 12(5) 449-459)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Switzerland, dexmethylphenidate XR was licensed for use in adults in 2009 and has been reported as a safe and effective option.
“In Switzerland Dexmethylphenidate XR was licensed for use in adults in 2009 and this has been reported as a safe and effective option [292].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [292]
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,767 · see citing works
KESSLER, R. C., ADLER, L., AMES, M., DEMLER, O., FARAONE, S., HIRIPI, E., HOWES, M. J., JIN, R., SECNIK, K., SPENCER, T., et al. (2005) · Psychological Medicine · doi:10.1017/s0033291704002892 · Cited by 3,452 · see citing works
Self-citationECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896 · see citing works
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · see citing works
Self-citationSpencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385 · see citing works
Self-citationAttention-Deficit/Hyperactivity Disorder in Adults
Wilens, T. E. (2004) · JAMA · doi:10.1001/jama.292.5.619 · Cited by 335 · see citing works
Kessler, R. C., Adler, L., Ames, M., Barkley, R. A., Birnbaum, H., Greenberg, P., Johnston, J. A., Spencer, T., & ??st??n, T. B. (2005) · Journal of Occupational and Environmental Medicine · doi:10.1097/01.jom.0000166863.33541.39 · Cited by 335 · see citing works
Self-citationDiagnosis and evaluation of adults with attention-deficit/hyperactivity disorder
Adler, L., & Cohen, J. (2004) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2003.12.003 · Cited by 290 · see citing works
Self-citationSpencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J., & Bearman, S. K. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.8.775 · Cited by 250 · see citing works
Self-citationComorbidities and Costs of Adult Patients Diagnosed with Attention-Deficit Hyperactivity Disorder
Secnik, K., Swensen, A., & Lage, M. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523010-00008 · Cited by 247 · see citing works
Swanson, J. M., Wigal, S. B., Wigal, T., Sonuga-Barke, E., Greenhill, L. L., Biederman, J., Kollins, S., Nguyen, A. S., DeCory, H. H., Hirshe Dirksen, S. J., et al. (2004) · Pediatrics · doi:10.1542/peds.113.3.e206 · Cited by 238 · see citing works
Keating, G. M., & Figgitt, D. P. (2002) · Drugs · doi:10.2165/00003495-200262130-00009 · Cited by 201 · see citing works
Ding, Y.-S., Fowler, J. S., Volkow, N. D., Dewey, S. L., Wang, G.-J., Logan, J., Gatley, S. J., & Pappas, N. (1997) · Psychopharmacology · doi:10.1007/s002130050267 · Cited by 157 · see citing works
Spencer, T. J., Adler, L. A., McGough, J. J., Muniz, R., Jiang, H., & Pestreich, L. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.032 · Cited by 155 · see citing works
Self-citationSrinivas, N. R., Hubbard, J. W., Quinn, D., & Midha, K. K. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.185 · Cited by 120 · see citing works
Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans
Srinivas, N. R., Hubbard, J. W., Korchinski, E. D., & Midha, K. K. (1993) · Pharmaceutical Research · doi:10.1023/a:1018956526016 · Cited by 105 · see citing works
WIGAL, S., SWANSON, J. M., FEIFEL, D., SANGAL, R. B., ELIA, J., CASAT, C. D., ZELDIS, J. B., & CONNERS, C. K. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000138351.98604.92 · Cited by 101 · see citing works
Quinn, D., Wigal, S. B., Swanson, J. M., Hirsch, S., OTTOLINI, Y. L., Dariani, M., Roffman, M., Zeldis, J. B., & Cooper, T. B. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000140455.96946.2b · Cited by 79 · see citing works
Nonstimulant treatment of adult attention-deficit/hyperactivity disorder
Spencer, T. J., Biederman, J., & Wilens, T. E. (2004) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2003.12.001 · Cited by 65 · see citing works
Self-citationCarbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain.
Ding, Y., Fowler, J. S., Volkow, N. D., Logan, J., Gatley, S. J., & Sugano, Y. (1995) · PubMed · Cited by 61 · see citing works
Stimulant treatment of adult attention-deficit/hyperactivity disorder
Spencer, T. J., Biederman, J., & Wilens, T. E. (2004) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2003.12.002 · Cited by 52 · see citing works
Self-citationDie Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen
Krause, J. (2007) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2005-919081 · Cited by 42 · see citing works
Flagged first, then by citations
1 of the 24 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Kooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928 · see citing works
“In Switzerland Dexmethylphenidate XR was licensed for use in adults in 2009 and this has been reported as a safe and effective option [292].”
Fredriksen, M., Halmøy, A., Faraone, S. V., & Haavik, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.016 · Cited by 173 · see citing works
Attention deficit hyperactivity disorder in adults
Rösler, M., Casas, M., Konofal, É., & Buitelaar, J. K. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.483249 · Cited by 140 · see citing works
“Improvement in both measures was evident from Week 1 onwards (Adler et al. 2008).”
InfluentialPrescription stimulant medication misuse: Where are we and where do we go from here?
Weyandt, L. L., Oster, D. R., Marraccini, M. E., Guðmundsdóttir, B. G., Munro, B. A., Rathkey, E. S., & McCallum, A. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000093 · Cited by 135 · see citing works
An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults
Wilens, T. E., Morrison, N. R., & Prince, J. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.137 · Cited by 113 · see citing works
Ginsberg, Y., & Lindefors, N. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.092940 · Cited by 99 · see citing works
“16 16–19 Despite the high prevalence of ADHD in prison inmates, pharmacological treatment has not been evaluated in this group.”
InfluentialWeyandt, L. L., Marraccini, M. E., Guðmundsdóttir, B. G., Zavras, B. M., Turcotte, K., Munro, B. A., & Amoroso, A. J. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0034013 · Cited by 92 · see citing works
Weyandt, L. L., Oster, D. R., Marraccini, M. E., Guðmundsdóttir, B. G., Munro, B. A., Zavras, B. M., & Kuhar, B. G. (2014) · Psychology Research and Behavior Management · doi:10.2147/prbm.s47013 · Cited by 84 · see citing works
Fuermaier, A. B. M., Tucha, L., Koerts, J., van Heuvelen, M. J. G., van der Zee, E. A., Lange, K. W., & Tucha, O. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090747 · Cited by 82 · see citing works
“headache [20].”
Fredriksen, M., Dahl, A. A., Martinsen, E. W., Klungsøyr, O., Haavik, J., & Peleikis, D. E. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.09.013 · Cited by 63 · see citing works
Santosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62 · see citing works
“In the 6-month open-label extension of the trial of dexmethylphenidate ER,([63]) the most common adverse effects were headache (27.”
BackgroundInfluentialHuss, M., Ginsberg, Y., Tvedten, T., Arngrim, T., Philipsen, A., Carter, K., Chen, C.-W., & Kumar, V. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0085-5 · Cited by 61 · see citing works
“Nonetheless, the efficacy and safety of MPH has been evaluated in ADHD patients with co-morbid conditions in other studies [24, 34, 37].”
BackgroundBain, E., Robieson, W., Pritchett, Y., Garimella, T. S., Abi‐Saab, W., Apostol, G., McGough, J. J., & Saltarelli, M. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.194 · Cited by 55 · see citing works
“Although safety concerns, including cardiovascular risks, sleep disturbances (Adler et al, 2006, 2009; Weisler et al, 2009), and the potential for growth suppression (Biederman et al, 2003; Faraone et al, 2005; Pliszka et al, 2006b; Spencer et al, 2006, 2007; reviewed by Vitiello, 2008), have been…”
Self-citationLong-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder
Huang, Y., & Tsai, M.-H. (2011) · CNS Drugs · doi:10.2165/11589380-000000000-00000 · Cited by 54 · see citing works
“However, various methylphenidate formulations – including OROS methylphenidate, extended-release methylphenidate and dexmethylphenidate – were recently concluded to be effective and safe during 6-month to 2-year treatment periods for adult ADHD.([119-124]) Longterm atomoxetine treatment was also shown to be effective…”
Pharmacotherapy of ADHD in Adults
Wilens, T. E. (2008) · CNS Spectrums · doi:10.1017/s1092852900002960 · Cited by 50 · see citing works
Goodman, D. W., & Thase, M. E. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2049 · Cited by 46 · see citing works
Health Care Services for Adults With ADHD: Patient Satisfaction and the Role of Psycho-Education
Solberg, B., Haavik, J., & Halmøy, A. (2019) · Journal of Attention Disorders · doi:10.1177/1087054715587941 · Cited by 33 · see citing works
Arnold, V. K., Feifel, D., Earl, C. Q., Yang, R., & Adler, L. A. (2014) · Journal of Attention Disorders · doi:10.1177/1087054712441969 · Cited by 48 · see citing works
Self-citationErmer, J. C., Dennis, K., Haffey, M. B., Doll, W. J., Sandefer, E. P., Buckwalter, M., Page, R. C., Diehl, B., & Martin, P. T. (2011) · Clinical Drug Investigation · doi:10.2165/11588190-000000000-00000 · Cited by 35 · see citing works
Mattingly, G. W., Weisler, R. H., Young, J. L., Adeyi, B. A., Dirks, B., Babcock, T., Lasser, R. A., Scheckner, B., & Goodman, D. W. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-39 · Cited by 32 · see citing works
“of global improvement at endpoint [3,4,25].”
BackgroundFredriksen, M., & Peleikis, D. E. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12477 · Cited by 31 · see citing works
“The improvements of global severity and function and the reduction of mental distress (GSI) also correspond well with broader outcomes found in studies exploring such characteristics (Wender et al. 2011, Weiss et al. 2010, Ginsberg & Lindefors 2012, Adler et al. 2009b).”
BackgroundResultInfluentialMoen, M. D., & Keam, S. J. (2009) · CNS Drugs · doi:10.2165/11201140-000000000-00000 · Cited by 27 · see citing works
Oros Methylphenidate in the Treatment of Adults with Adhd: A 6-Month, Open-Label, Follow-Up Study
Marchant, B. K., Reimherr, F. W., Halls, C., Williams, E. D., & Strong, R. E. (2010) · Annals of Clinical Psychiatry · doi:10.1177/104012371002200309 · Cited by 27 · see citing works
Whole-body vibration improves cognitive functions of an adult with ADHD
Fuermaier, A. B. M., Tucha, L., Koerts, J., van den Bos, M., Regterschot, G. R. H., Zeinstra, E. B., van Heuvelen, M. J. G., van der Zee, E. A., Lange, K. W., & Tucha, O. M. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0149-7 · Cited by 25 · see citing works
“…drug treatment is associated with disadvantageous affecting a considerable proportion of patients, such as unsatisfactory effects, adverse clinical side effects (e.g., headache, dry mouth and insomnia) or high financial costs (Adler et al. 2009; Wigal et al. 1999; Wilens et al. 2002).”
BackgroundAttention-deficit/hyperactivity disorder in adults: update on clinical presentation and care
Asherson, P., Manor, I., & Huss, M. (2014) · Neuropsychiatry · doi:10.2217/npy.14.16 · Cited by 31 · see citing works
Changes in behavior as side effects in methylphenidate treatment: review of the literature
Konrad-Bindl, D. S., Gresser, U., & Richartz, B. M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114185 · Cited by 24 · see citing works
“Adler et al mentioned specifically instructing participants to report psychotic side effects, and that participants reported mania, aggression, and paranoia.(51) However, during their presentation of results, the authors”
Silva, R. R., Skimming, J. W., & Muniz, R. (2010) · Clinical Pediatrics · doi:10.1177/0009922810368289 · Cited by 22 · see citing works
“MAS-XR (10-60 mg/d) 11% (29/258) Biederman et al17 (19-60) Pulse > 100 bpm (P = .”
Self-citationDuration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration
Zimmerman, K. O., Smith, P. B., McMahon, A. W., Temeck, J. W., Avant, D. A., Murphy, D., & McCune, S. (2018) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2018.3227 · Cited by 21 · see citing works
“Third, short-term and longer-term evaluations of stimulants have been associated with insomnia, concern for abnormal cognitive development, and impaired growth; quantification of risks are not fully elucidated.(22-24) Mood stabilizers and antipsychotics have shown associations with weight gain and metabolic derangemen…”
Edvinsson, D., & Ekselius, L. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000917 · Cited by 21 · see citing works
Prescription Stimulant Misuse and ADHD Symptomatology Among College Students in Iceland
Guðmundsdóttir, B. G. (2015) · doi:10.23860/diss-gudmundsdottir-bergljot-2015 · Cited by 21 · see citing works
The safety of extended-release drug formulations for the treatment of ADHD
Childress, A. C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1317344 · Cited by 19 · see citing works
“OROS MPH [48] significantly > placebo in 34week trial LDX [49] >5% in 12-month open-label study (any dose) MAS-XR [80] Treatmentrelated up to 24 months, open label d-MPH-ER [51] >5% in 6-month open-label study (any dose)”
BackgroundGinsberg, Y., Arngrim, T., Philipsen, A., Gandhi, P., Chen, C.-W., Kumar, V., & Huss, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0180-4 · Cited by 20 · see citing works
“on safety and efficacy of dexmethylphenidate extended release (d-MPH-ER) (20–40 mg/day) [29].”
BackgroundResultLinderkamp, F., & Lauth, G. W. (2011) · Verhaltenstherapie · doi:10.1159/000332429 · Cited by 17 · see citing works
Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K., Paludan‐Müller, A. S., Gøtzsche, P. C., & Jørgensen, K. J. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012857.pub2 · Cited by 21 · see citing works
Personality Disorder in Adult Attention-Deficit/Hyperactivity Disorder
Gift, T. E., Reimherr, F. W., Marchant, B. K., Steans, T. A., & Wender, P. H. (2016) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000470 · Cited by 15 · see citing works
“Adler et al. (2009) reported that 60% of subjects entering the longterm portion of their study with dexmethylphenidate completed the study, whereas Adler et al. (2011) reported that 57% of subjects entering the long-term portion of their study with OROS MPH completed 6 months of the study.”
BackgroundHuss, M., Ginsberg, Y., Arngrim, T., Philipsen, A., Carter, K., Chen, C.-W., Gandhi, P., & Kumar, V. (2014) · Clinical drug investigation · doi:10.1007/s40261-014-0213-2 · Cited by 11 · see citing works
“The safety and tolerability observed in this study are similar to those reported in children and are consistent with the known effects of methylphenidate or other stimulant medications [12, 13].”
ResultPharmacotherapy of ADHD in adults
Prince, J. B., Morrison, N. R., & Wilens, T. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.023 · Cited by 11 · see citing works
Treating Attention-Deficit/Hyperactivity Disorder in Adults
Weisler, R. H., & Childress, A. C. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11r01168 · Cited by 10 · see citing works
Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder
Anbarasan, D., Safyer, G., & Adler, L. A. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.008 · Cited by 9 · see citing works
Self-citationAdler, L. A., Frick, G. S., & Yan, B. M. (2017) · Journal of Attention Disorders · doi:10.1177/1087054717696770 · Cited by 9 · see citing works
Self-citationSopko, M. A., Caberwal, H., & Chavez, B. (2010) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4178 · Cited by 8 · see citing works
“All P , 0.05) No statistically significant changes in BP 51 sites in europe, 98% Caucasian, 71% w/ADHD combined subtype Adler et al 2009 (OROS MPH) DB, randomized to MPH or PLA in ratio of 1:1, parallel, PLAcontrolled, doseescalation, 7 wks in 27 sites, iTT w/ LOCF 18–65 yrs, Met DSM-iv-TR criteria…”
InfluentialRamsay, J. R., & Rostain, A. L. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.030 · Cited by 6 · see citing works
Brancati, G. E., Dominicis, F. D., Petrucci, A., Pallucchini, A., Carli, M., Medda, P., Schiavi, E., Rossi, P. D., Vicari, S., & Perugi, G. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2168750 · Cited by 5 · see citing works
Dexmethylphenidate for attention deficit hyperactivity disorder
Coury, D. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903386284 · Cited by 2 · see citing works
“[21] reported on these102 adults showing sustained benefits from dMPH with mean reduction of global assessment of functioning (GAF) scores from a level of moderate difficulty to a level consistent with only slight impairment of functioning.”
BackgroundEdvinsson, D. (2017) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 3 · see citing works
A META-ANALYSIS OF PRESCRIPTION STIMULANT EFFICACY: ARE STIMULANTS NEUROCOGNITIVE ENHANCERS?
Marraccini, M. E. (2015) · doi:10.23860/diss-marraccini-marisa-2015 · Cited by 2 · see citing works
“, Adler et al., 2008; Adler et al., 2009; Bouffard, Hechtman, Minde, & Iboni-Kassab, 2003; Faraone, 2012; Jain et al., 2007; Kooij et al., 2004; Spencer et al., 2005; Spencer et al., 2007; Spencer, Adler, Weisler, & Youcha, 2008; Stein et al., 2011; Weisler et al., 2006). A recent metaanalysis conducted by Faraone and…”
BackgroundAttention deficit hyperactivity disorder in prison inmates
Ginsberg, Y. (2012) · Figshare · Cited by 2 · see citing works
Roberts, J. (2023) · Scholarworks (University of Massachusetts Amherst) · doi:10.7275/1942366 · Cited by 2 · see citing works
College Readiness: Differences Between Students With And Without ADHD
Ranson, L. M. (2017) · Figshare · doi:10.71889/5fylantbak.29862113 · Cited by 1 · see citing works
Whole body vibration als nieuwe behandeling voor cognitieve disfuncties bij ADHD?
Fuermaier, A. B. M., Tucha, L., de Vries, S. M., Koerts, J., van Heuvelen, M. J. G., van der Zee, E. A., & Tucha, O. M. (2016) · Neuropraxis · doi:10.1007/s12474-015-0108-x
“Vooral klinische bijwerkingen, zoals een droge mond, verminderde eetlust en hoofdpijn, kunnen optreden, met name in combinatie met stimulantia [19].”
BackgroundMasche, U. (2011) · pharma-kritik · doi:10.37667/pk.2011.851
- Authors
- Adler, L. A., Spencer, T., McGough, J. J., Jiang, H., & Muniz, R.
- Affiliations
- VA NY Harbor Healthcare System (US)
- Massachusetts General Hospital (US)
- University of California, Los Angeles (US)
- The Adult ADHD Research Group, Novartis Pharmaceuticals Corporation, East Hanover
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2009-03
- Volume
- 12
- Issue
- 5
- Pages
- 449-459
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2026549843
- Cited by
- 53
- References
- 24
- Citations by year
- 2023: 2 · 2022: 2 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 4 · 2014: 11 · 2013: 3 · 2012: 4
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- adult ADHD, long-term treatment safety, ADHD symptom improvement, ADHD Rating Scale, flexible dosing, adverse events, stimulant medication
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Capsules, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Methylphenidate, Middle Aged, Personality Assessment, Treatment Outcome, Adverse Drug Reaction Reporting Systems, Young Adult, Dexmethylphenidate Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
